Back to Results

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc. is a clinical-stage biotechnology company focused on immuno-oncology in the United States. The company is developing allogeneic stem cell-based and enveloped virus platforms designed to support the delivery of oncolytic viruses. Its pipeline includes CLD-101, which is being studied in Phase 1b/2 and Phase 1 dose-escalation trials for high-grade glioma and recurrent high-grade glioma, respectively. Other programs include CLD-201 for several solid tumors, CLD-301 for multiple indications, and CLD-400 for certain lung cancer and metastatic solid tumors. Calidi also works with virus platforms under names such as NeuroNova, SuperNova, and RTNova. The company was founded in 2014 and is based in San Diego, California. The listed security is common stock on the NYSE.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NYSE-CLDI
$1.24
12.9% Upside
Fair
Not available
Not available
Weak
0.0%
November 17, 2026
1.3x
4.065 M
1.936 M
37.7%
98.9%
-36.5
76.1%
Valuation • Fair Value

Calidi Biotherapeutics Inc (NYSE-CLDI) Fair Value by Valuation Model

Review the available estimates for Calidi Biotherapeutics Inc (NYSE-CLDI), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.24

Estimated upside of 12.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.24

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Calidi Biotherapeutics Inc (NYSE-CLDI) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Calidi Biotherapeutics Inc (NYSE-CLDI)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-16.137 M

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Calidi Biotherapeutics Inc (NYSE-CLDI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Calidi Biotherapeutics Inc (NYSE-CLDI)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

-36.5

Lower score that deserves closer risk review.

FCF / Net Income

76.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Calidi Biotherapeutics Inc (NYSE-CLDI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Calidi Biotherapeutics Inc (NYSE-CLDI)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 17, 2026

Days to Earnings

60

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Calidi Biotherapeutics Inc (NYSE-CLDI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Calidi Biotherapeutics Inc (NYSE-CLDI) Stock Forecast & Technical Outlook

Review Calidi Biotherapeutics Inc (NYSE-CLDI) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Calidi Biotherapeutics Inc (NYSE-CLDI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Calidi Biotherapeutics Inc (NYSE-CLDI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Calidi Biotherapeutics Inc (NYSE-CLDI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Calidi Biotherapeutics Inc (NYSE-CLDI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Calidi Biotherapeutics Inc (NYSE-CLDI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Calidi Biotherapeutics Inc (NYSE-CLDI)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Calidi Biotherapeutics Inc (NYSE-CLDI) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Calidi Biotherapeutics Inc (NYSE-CLDI) Stock FAQ

Data-supported answers about Calidi Biotherapeutics Inc (NYSE-CLDI), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.24
Estimated upside 12.9%
Valuation Rating
Undervalued
Estimated upside of 12.9%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Calidi Biotherapeutics Inc (NYSE-CLDI) is $1.24. This implies an estimated upside of 12.9% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 12.9% versus the current market price.

The current financial health read for Calidi Biotherapeutics Inc (NYSE-CLDI) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Calidi Biotherapeutics Inc (NYSE-CLDI) is November 17, 2026.

The latest available data indicates no current dividend yield for Calidi Biotherapeutics Inc (NYSE-CLDI).

The current market capitalization listed for Calidi Biotherapeutics Inc is 4.065 M.

The current enterprise value listed for Calidi Biotherapeutics Inc is 1.936 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Calidi Biotherapeutics Inc is NYSE-CLDI, and the stock is listed on NYSE.

Calidi Biotherapeutics Inc (NYSE-CLDI) is listed on NYSE.

The current debt-to-total-capital ratio listed for Calidi Biotherapeutics Inc is 37.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Calidi Biotherapeutics Inc is 98.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NYSE

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B